Nymox Pharmaceutical Corporation (NYMX) and XBiotech Inc. (NASDAQ:XBIT) Comparison side by side

Both Nymox Pharmaceutical Corporation (NASDAQ:NYMX) and XBiotech Inc. (NASDAQ:XBIT) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nymox Pharmaceutical Corporation N/A 621.70 10.80M -0.18 0.00
XBiotech Inc. N/A 0.00 22.93M -0.64 0.00

Table 1 demonstrates Nymox Pharmaceutical Corporation and XBiotech Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Nymox Pharmaceutical Corporation (NASDAQ:NYMX) and XBiotech Inc. (NASDAQ:XBIT)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Nymox Pharmaceutical Corporation 0.00% -315.3% -223.3%
XBiotech Inc. 0.00% -51.9% -48.9%

Risk & Volatility

Nymox Pharmaceutical Corporation’s 1.97 beta indicates that its volatility is 97.00% more volatile than that of S&P 500. XBiotech Inc.’s 77.00% less volatile than S&P 500 which is a result of the 0.23 beta.

Liquidity

Nymox Pharmaceutical Corporation’s Current Ratio is 7.5 while its Quick Ratio is 7.4. On the competitive side is, XBiotech Inc. which has a 4.6 Current Ratio and a 4.6 Quick Ratio. Nymox Pharmaceutical Corporation is better positioned to pay off short and long-term obligations compared to XBiotech Inc.

Institutional and Insider Ownership

Nymox Pharmaceutical Corporation and XBiotech Inc. has shares held by institutional investors as follows: 6.3% and 13.5%. 5.2% are Nymox Pharmaceutical Corporation’s share held by insiders. Competitively, XBiotech Inc. has 37.8% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Nymox Pharmaceutical Corporation -1.16% -4.76% -31.45% -17.07% -56.85% 29.77%
XBiotech Inc. -1.05% 4.56% 14.22% 144.16% 114.12% 85.04%

For the past year Nymox Pharmaceutical Corporation has weaker performance than XBiotech Inc.

Summary

Nymox Pharmaceutical Corporation beats on 4 of the 7 factors XBiotech Inc.

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of AlzheimerÂ’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.